The Pharmacy Times® Allergy Resource Center is a comprehensive resource for clinical news and expert insights on issues related to conditions that cause the immune system to react abnormally to a foreign substance, including seasonal allergies, food allergies, drug allergies, and contact dermatitis.
May 16th 2025
Omalizumab expands its role in allergy management, now FDA-approved for food allergies, showcasing potential for broader applications in allergic rhinitis.
FDA Approves Dupilumab, Marking First Targeted Therapy in a Decade for Chronic Spontaneous Urticaria
Published: April 18th 2025 | Updated: April 18th 2025Multiple phase 3 clinical trials demonstrated dupilumab’s (Dupixent; Regeneron, Sanofi) effectiveness in reducing hives and itch in patients with chronic spontaneous urticaria compared with placebo.
Read More